



Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors

This is the peer reviewed version of the following article:

Original:

Elgaher, W.A.M., Sharma, K.K., Hauptenthal, J., Saladini, F., Pires, M., Real, E., et al. (2016). Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors. JOURNAL OF MEDICINAL CHEMISTRY, 59(15), 7212-7222 [10.1021/acs.jmedchem.6b00730].

Availability:

This version is available <http://hdl.handle.net/11365/1079454> since 2019-09-09T16:58:07Z

Published:

DOI:10.1021/acs.jmedchem.6b00730

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-Carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors

Walid A. M. Elgaher,[†] Kamal K. Sharma,[‡] Jörg Haupenthal,[†] Francesco Saladini,[§] Manuel Pires,[‡] Eleonore Real,[‡] Yves Mély,[‡] and Rolf W. Hartmann^{*†}

[†]Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Department of Drug Design and Optimization & Saarland University, Pharmaceutical and Medicinal Chemistry, Campus E8.1, 66123 Saarbrücken, Germany

[‡]Laboratoire de Biophotonique et Pharmacologie, UMR 7213 CNRS, Université de Strasbourg, Faculté de pharmacie, 74 route du Rhin, 67401 Illkirch, France

[§]Department of Medical Biotechnologies, University of Siena, Viale Mario Bracci 16, 53100 Siena, Italy

ABSTRACT

We are concerned with the development of novel anti-infectives with dual antibacterial and antiretroviral activities for MRSA/HIV-1 co-infection. To achieve this goal, we exploited for the first time the mechanistic function similarity between the bacterial RNA polymerase (RNAP) “switch region” and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site. Starting from our previously discovered RNAP inhibitors, we managed to develop potent RT inhibitors effective against several resistant HIV-1 strains with maintained or enhanced RNAP inhibitory properties following a structure-based design approach. A quantitative structure–activity relationship (QSAR) analysis revealed distinct molecular features necessary for RT inhibition. Furthermore, mode of action (MoA) studies revealed that these compounds inhibit RT non-competitively, through a new mechanism via closing of the RT clamp. In addition, the novel RNAP/RT inhibitors are characterized by a potent antibacterial activity against *S. aureus* and *in cellulo* antiretroviral activity against NNRTI-resistant strains. Using HeLa and HEK 293 cells the compounds showed only marginal cytotoxicity.

INTRODUCTION

Human immunodeficiency virus type 1 (HIV-1) is the causative agent of the acquired immune deficiency syndrome (AIDS), which is one of the major lethal infectious diseases endangering humanity. In 2014, more than 37 million people worldwide were HIV-infected with a mortality of approximately 1.2 million.¹ The HIV-1 retrovirus targets the CD4 cells resulting in an impairment of the immune system. In consequence, HIV patients are a defenseless prey for bacterial infections e.g. tuberculosis (TB) and methicillin-resistant *Staphylococcus aureus* (MRSA).²⁻⁴ MRSA co-infection is characterized by a high incidence rate.⁵ In addition, the emergence of multidrug resistant MRSA markedly increased among HIV patients.^{6,7} Current treatment of HIV infection requires a combination of at least three antiretroviral drugs. This highly active antiretroviral therapy (HAART) permits efficient suppression of virus replication and inhibits disease progression. However, the evolution of antiretroviral drug resistance is still presenting an intractable problem due to the high viral mutation rate and non-compliance to antiretroviral therapy (ART).⁸⁻¹⁰ Although the FDA recently approved a combined ART as one pill daily that could improve patient adherence,¹¹ the resistance issue is not yet solved. Treatment of MRSA/HIV-1 co-infection is even more challenging. In addition to the above mentioned issues, administration of antibiotics should take into consideration the ongoing prevalence of resistant bacteria in HIV-1 populations,^{6,7} as well as potential drug interactions between antiretroviral and antibacterial agents.¹² Hence, there is an urgent need for a one compound therapy of MRSA/HIV-1 co-infections. Combining antibacterial and antiretroviral properties in a single molecule should be beneficial in different aspects: it will improve patient adherence to ART by reduction of medications' regimen,¹¹ and consequently decrease the probability of treatment failure. Moreover, prescribing such anti-infective medication will avoid drug interactions,¹² and lower the costs of care as well.¹³

HIV-1 RT is a key target for ART. It reverse-transcribes the single-stranded viral RNA to double-stranded DNA, which is essential for virus replication.¹⁴ There are two main classes inhibiting RT: nucleoside RT inhibitors (NRTIs) and NNRTIs. NRTIs are nucleotide analogues that are incorporated into viral DNA leading to chain termination. Through binding to an allosteric binding site, NNRTIs inhibit RT non-competitively.^{15,16} In bacteria, RNAP is an essential enzyme for bacterial viability¹⁷

1
2
3 and has consequently become a pivotal drug target. It is responsible for transcription by converting
4 double-stranded DNA to single-stranded RNA, which is a prerequisite for protein synthesis.
5
6
7 Consequently, there is a functional relationship between bacterial RNAP and viral RT. In this context,
8
9 the clinically used RNAP inhibitor rifampicin does also inhibit viral RT.¹⁸ On the other side, HIV-1
10
11 RT monoclonal antibodies were found to inhibit *E. coli* RNAP, indicating structural and functional
12
13 similarities between both enzymes.¹⁹ Recently, a new RNAP binding site, the “switch region”, was
14
15 discovered with a mechanistic function close to that of the NNRTI binding site.²⁰ However, these
16
17 important insights have not yet been exploited for drug discovery.

18
19 In previous works, we developed new classes of RNAP “switch region” inhibitors using different drug
20
21 design approaches.^{21,22} Their mode of action was confirmed by biophysical methods and mutation
22
23 studies.²³ Beside their activity against MRSA, the compounds showed no cross-resistance with
24
25 rifampicin and a low rate of resistance development in *E.coli* TolC.^{22,23} Thus, our RNAP inhibitors
26
27 should be a good starting point for designing such dual acting anti-infectives. For testing our
28
29 compounds for RT inhibition, we applied our recently developed Förster resonance energy transfer
30
31 (FRET) based polymerization assay.²⁴ Nevirapine (NVP) as an NNRTI and zidovudine (AZT-TP) as
32
33 an NRTI were used as references. For hit optimization, we employed a structure-based design
34
35 approach. Indeed, we succeeded in developing the first anti-infectives with dual antibacterial and
36
37 antiretroviral activities.

38 39 40 41 **RESULTS AND DISCUSSION**

42 43 **Design of Compounds and SAR**

44
45 In order to identify the privileged scaffold for HIV-1 RT inhibition among various classes of switch
46
47 region binding RNAP inhibitors, we selected eight compounds representing four regioisomeric
48
49 ureidothiophenes (Chart 1).
50
51
52
53
54
55
56
57
58
59
60




Chart 1. Structures of the ureidothiophene regioisomers used for finding the privileged scaffold for RT inhibition.

Results revealed that only compound **4** (class II) showed a high RT inhibitory activity ($IC_{50} = 0.9 \mu\text{M}$, Table 1). This indicates that the introduction of an additional chlorine substituent in the 3-position of the phenyl ring leads to a dramatic increase in potency (**4** vs **3**), which is more pronounced than observed for RNAP inhibition.^{21,22} Comparing class II compounds which are highly similar to compounds of class I (the only difference is the position of the S in the thiophene ring) and had shown similar RNAP inhibition,²² strong differences regarding the inhibition of RT were observed, too. This finding can be attributed to the different binding sites and the slight differences in the molecular properties of the ligands. Comparing the RNAP “switch region” and the RT allosteric binding site, it becomes apparent that both pockets are mainly hydrophobic. The RNAP “switch region” is U-shaped with a cavity volume of $\sim 500 \text{ \AA}^3$.²⁵ The RT allosteric binding site is highly flexible regarding size, i.e. it is nonexistent in absence of NNRTIs,^{26,27} whereas it possesses a cavity volume of $620\text{--}720 \text{ \AA}^3$ in presence of NNRTIs.¹⁴ Analyzing the molecular similarity between class I and II *in silico* by a 4-point pharmacophore fingerprint method²⁸ and the Tanimoto coefficient (T_C) as a similarity metric, class I


showed partial similarity to II ($T_C = 0.75$). This is in contrast to the results obtained recently using a 3-point pharmacophore as a fingerprint.²² As **4** was the only compound showing a strong inhibition against both enzymes, we focused on class II as the most appropriate scaffold for the development of dual RNAP and RT inhibitors.

Table 1. *In Vitro* Inhibitory Activities of Compounds **1–8** against HIV-1 RT and *E. coli* RNAP

Compound	% inhibition of HIV-1 RT at 1 μ M	IC ₅₀ <i>E. coli</i> RNAP (μ M)
1	12 ^a	75
2	24 ^a	22
3	12	54
4	0.9 ^b	21
5	12	> 100
6	12	57
7	13 ^c	> 200
8	4 ^c	100

^a% inhibition at 25 μ M; ^bIC₅₀ value (μ M); ^c% inhibition at 10 μ M.

In the next step, we varied the substituents at the ureido motif of **4** (compounds **9–11**, Table 2). While increasing bulkiness and lipophilicity at the ureido motif led to a potent RNAP inhibitory activity (**10**),^{21,22} the RT inhibitory activities observed for compounds **9–11** were surprising. Exchange of the ethyl substituent by a hydrogen (**9**) as well as by a sterically demanding benzyl substituent (**10**) reduced activity drastically. Activity was restored by omitting the methylene spacer of the R¹ substituent in **9**, i.e. exchanging the benzyl group by a phenyl (**11**). As compound **11** shows a better ligand efficiency²⁹ and ligand-lipophilicity efficiency²⁹ compared to **4** (LE: 0.32 vs 0.29; LLE: 2.51 vs 2.33), the subsequent structure modifications were performed based on this compound.

Table 2. *In Vitro* Inhibitory Activities of Compounds 9–20 against HIV-1 RT and *E. coli* RNAP

Compound	R ¹	R ²	IC ₅₀ HIV-1 RT (μM)	IC ₅₀ <i>E. coli</i> RNAP (μM)
4			0.9	21
9		H	64 ^a	43
10			63 ^a	7
11		H	1.2	20
12		H	0.7	14
13		H	0.8	22
14		H	64 ^a	53
15		H	0.6	27
16		H	0.8	40
17		H	0.3	19
18		H	0.1	26
19		H	0.9	8
20		H	0.6	23
NVP	-	-	0.1	> 200
AZT-TP	-	-	7.0	n.d. ^b

^a% inhibition at 25 μM; ^b not determined.

In order to reduce the number of compounds to be synthesized, we followed a structure-based design strategy. Using a high resolution co-crystal of the RT–NVP complex (PDB code 1VRT),¹⁴ we performed an induced fit molecular docking of **11** into the RT allosteric binding site. The compound adopted a U-shape stabilized by an intramolecular hydrogen bond between the ureido NH and the carboxylate group forming a six membered ring (Figure 1). The thiophene core is located lowermost near the cavity entrance, while the 3,4-dichlorophenyl and the N-phenyl moieties are positioned uppermost overlapping the two pyridine rings of NVP. Four hydrophobic interactions characterize the binding of **11** to the NNRTI binding pocket. Two arene–H interactions can be observed between Leu100 and the thiophene core as well as Leu100 and the 3,4-dichlorophenyl moiety. The latter also binds to Val106 through an arene–H interaction from the other side. The fourth interaction is an edge-to-face (T-shaped) arene interaction between Trp229 and the *m*-position of the N-phenyl group. Binding is further strengthened through a hydrogen bond interaction between Lys101 and the carboxylate C=O group.




Figure 1. (A) Docking pose of **11** (magenta) compared to NVP (orange) in the RT allosteric binding site: hydrophobic surface (green), polar surface (pink); (B) 2D ligand interactions of **11**.

1
2
3 According to the docking results, all three aromatic motifs of **11** are essential for binding. Moreover,
4 no π - π contacts between **11** and the frequently mutated amino acids Tyr181 and Tyr188¹⁰ were
5 observed. Interestingly, mutations of the amino acids in contact with **11** are known to result in high
6 (Trp229, Val106, Leu100) and low fitness costs (Lys101).^{10,30-32}

7
8
9 Since Trp229, Phe227 and Leu234 belong to the polymerization-essential “primer grip” and are
10 known to show low mutation frequency,^{14,32,33} we further optimized our compounds for interaction
11 with these highly conserved residues. To achieve this goal, we exploited the space between the *p*-
12 position of the N-phenyl moiety and this conserved region by introduction of diverse substituents with
13 varying bulkiness, electronic and lipophilic properties (**12–20**, Table 2). Results indicate that except
14 for compound **14**, the new modifications improve the activity up to 12-fold (**18**). The RT inhibitory
15 activity of compound **18** is comparable to that of NVP and significantly higher than that of AZT-TP.
16 Inspection of the substituent constants and molecular properties of the new compounds (Table S1)
17 reveals that hydrophilic and hydrogen bond donor/acceptor substituents at the N-phenyl group are
18 important for activity. Obviously, activity can be enhanced to a certain extent by increasing the
19 conformational flexibility of the compounds. Interestingly, introduction of aromatic moieties (phenyl
20 or 1,2,4-triazolyl) at the sulfonamide or the acetamide group negatively affects RT inhibitory activity
21 (**19** vs **18**, and **16** vs **15**) leading to the hypothesis that too bulky substituents at the ureido motif are
22 not favorable for RT inhibition. These findings are in agreement with our docking model (Figure 1), as
23 these aryl motifs elicit a steric clash with the amino acid residues (Tyr188, Phe227, Trp229 and
24 Leu234) lining the deep side of the NNRTI binding pocket. As a consequence of this, they either are
25 shifted in the binding cavity outward or adopt another conformation leading to lower binding
26 interaction.

27
28 For further SAR elucidation, we calculated a QSAR model for compounds **11–20** using a multiple
29 regression analysis

$$pIC_{50} = 4.83 + 1.15 PC^+ - 0.12 vsa_don - 0.27 SMR \quad (1)$$

$$(n = 10, R^2 = 0.94, RMSE = 0.13)$$

30
31
32 Where pIC_{50} is $-\log IC_{50}$, PC^+ is the total positive partial charge, vsa_don is the sum of van der Waals
33 surface areas of pure hydrogen bond donors, and SMR is molecular refractivity.

Equation 1 reveals a role of electrostatic and steric interactions for activity. Increasing the positive partial charge seems beneficial, whereas the number of hydrogen bond donor atoms at the N-phenyl moiety should be kept to a minimum (0–1 atoms). The inverse correlation with molecular refractivity underlines the importance of less polarizable and non-bulky substituents at the ureido motif for RT inhibition.

Regarding RNAP inhibition, the modifications were tolerated or even enhanced the activity (**12** and **19**). This could be attributed to the flexibility of this class of compounds and their ability to adopt more than one binding mode within the RNAP “switch region”.²³

Notably, as NVP shows no RNAP inhibitory activity, this stresses that the 2-ureidothiophen-3-carboxylic acids present a privileged structure for dual RNAP/RT inhibition. The fact that the new inhibitors show different activity profiles against the two target enzymes, resulting in compound **10** as the most potent RNAP inhibitor and **18** as the most active RT inhibitor, indicates specificity of the compounds and excludes promiscuity.

Mode of Action on RT Polymerization

To characterize the mode of action through which our compounds inhibit RT, we monitored first their effects on the binding parameters and orientation of RT on a model primer/template (p/t) duplex. To this end, we used a FRET assay with RT labeled by Alexa488 and a p/t duplex labeled by carboxytetramethylrhodamine (TAMRA).³⁴ The labeled RT mutant was found to bind to the p/t duplex with an affinity of ~3 nM (Figure S1 and Table S2), in good agreement with values reported for DNA p/t sequences in the literature (Table S2).³⁵ Interestingly, similar affinities as well as no change in RT orientation on the duplex were observed in the presence of compounds **4**, **11–13**, and **15–20**, indicating that these compounds marginally affected the binding of RT to the p/t duplexes, as anticipated for NNRTIs (Table S2).

In a next step, we investigated whether these compounds had the same mode of action as NNRTIs. As shown above, the latter bind usually to the hydrophobic pocket in the palm subdomain of p66 and inhibit RT via an allosteric mechanism,^{26,27,36} forcing the p66 thumb into an open extended position in respect to the finger domain, which prevents deoxyribonucleotides (dNTPs) incorporation³⁷ (Figure

S2C). In order to monitor the effect of our compounds on the relative motions of the thumb and finger domains, we developed a fluorescence-based assay with a RT double mutant where both Lys287 and Trp24 residues were replaced by cysteine residues.

By labeling the two Cys residues with Bodipy dyes, the intramolecular distance changes associated to the motion of RT's thumb and finger could be monitored by fluorescence spectroscopy. This distance is a key parameter as the relative separation between the thumb and finger subdomains defines the opening and closing of the clamp that holds and positions p/t duplexes at the polymerase active site (Figure S2B). A precise positioning of the primer 3'-end with respect to the polymerase active site (Asp110, Asp185 and Asp186) is required for the catalytic addition of a nucleotide. Due to the close proximity of the finger and thumb in the absence of p/t (Figure S2A), the two Bodipy probes were observed to quench each other, providing a low emission (Figure 2A).




Figure 2. Conformational changes of bodipy-labeled RT p66 W24C+K287C mutant. (A) Emission spectra of 60 nM bodipy-labeled RT in the absence (black line) or in the presence of 160 nM p/t duplex (red line) or 10 μ M NVP (green line); (B) Graph representing the ratio between the fluorescence intensities of the 100 nM doubly-labeled RT in presence of either the p/t duplex (160 nM) or NVP (10 μ M) or the tested compounds (3 μ M) to the fluorescence intensity of the free form. Red line corresponds to the best fit with linear regression ($y = m*x + b$), with values of slope (m) = 0.38 (\pm 0.04) μ M and intercept (b) = 0.25 (\pm 0.03). Excitation wavelength was 490 nm and ratios were calculated at emission wavelength of 510 nm; (C) Stopped-flow kinetic traces of 60 nM doubly labeled RT in the absence (red trace) and the presence of 10 μ M NVP (green trace) or compound **11** (blue trace). All traces were fitted by eq 2 and the rate constant values given in Table S2. Excitation wavelength was 490 nm and emission was collected by using a 525/50 nm band pass emission filter.

In contrast, a 1.6-fold increase in Bodipy fluorescence was observed on binding to p/t (Figure 2A and 2B), in line with the expected increase in the distance between the thumb and finger (Figure S2B). An even higher fluorescence increase (two-fold) was observed in the presence of NVP (Fig 2A and 2B), as anticipated from NVP's ability to further separate the two RT subdomains and block them in this open position (Figure S2C). Altogether, the data obtained with the Bodipy-labeled RT were fully consistent with the molecular structures of RT, validating this assay as a convenient means to investigate the inhibitory mechanisms of the synthesized RT inhibitors. In contrast to NVP and p/t duplex, a decrease in Bodipy fluorescence was observed with all tested compounds (Figure 2B). Since no fluorescence quenching was observed when free Bodipy was titrated to the compounds (data not shown), these compounds probably exerted an effect opposite to NVP, decreasing the distance between thumb and finger subdomains. Therefore, the compounds likely exert their inhibitory activity by blocking the RT clamp in a closed conformation.

To get further information on the inhibition mechanism of our compounds, we monitored the changes in fluorescence in real time by stopped-flow (Figure 2C and Table S2). Using NVP as a control, a mono-exponential increase of Bodipy emission was observed (Figure 2C and Table S2), suggesting that the NVP-induced opening of RT clamp occurs in a single step. The kinetic traces were fitted by using

$$I(t) = I_F - (I_F - I_0)e^{(-k_{obs}(t-t_0))} \quad (2)$$

where t_0 is the dead time, k_{obs} is the observed kinetic rate constant and I_0 and I_F are the fluorescence intensities before and after addition of inhibitors, respectively. The I_0 value was obtained from the steady-state fluorescence spectrum of the doubly labeled mutant and was thus fixed.

Similarly, a mono-exponential decrease in Bodipy emission was observed with all compounds (Figure 2C and Table S2), suggesting that they induce the closing of RT clamp, also in a single step. The kinetic rate constant values of all compounds were found to fluctuate in a narrow range, indicating that they exhibit similar mechanisms of RT inhibition. Interestingly, a clear correlation could be observed between the closing of the clamp and the IC_{50} values (Figure 2B). This indicates that the inhibitory activity of the compounds is related to their ability to efficiently close the RT clamp and thus, hinder the incorporation of dNTPs.

Antibacterial and Antiretroviral Activities

We complemented our *in vitro* results by firstly evaluating the activity of the new RNAP/RT inhibitors against *S. aureus*. Results revealed a high antibacterial effect for the majority of the compounds with minimum inhibitory concentrations (MICs) between 3–13 $\mu\text{g/mL}$ (Table 3). Markedly, these values correlate with the corresponding RNAP inhibitory activities. Secondly, we applied a cellular infectivity assay to assess the antiretroviral activity of our compounds. This assay is based on the infection of HeLa cells by a third generation of pseudoviral particles,³⁸ mimicking the early steps of the HIV-1 life cycle. Most of the tested compounds exhibited good antiretroviral activities in the low micromolar range (Table 3). Noticeably, a marked difference was observed in the activity profiles when comparing the *in vitro* and *in cellulo* results: The compounds turned out to be less active in the cellular system. This might be due to the lipophilic nature of the compounds leading to an inefficient permeation into the cells, or an interaction with other proteins in the antiviral assay leading to a lowered concentration at the target enzyme.

Next, we examined the effect of our compounds on cell viability in two different cell lines (HeLa and HEK 293) and found them to display only marginal or no cytotoxicity (Table 3).

Table 3. Antibacterial, Antiretroviral and Cytotoxic Activities of the Dual RNAP/RT Inhibitors.

Compound	MIC <i>S. aureus</i> ($\mu\text{g/mL}$)	IC ₅₀ Viral infectivity (μM)	% Inhibition of HeLa cell viability at 25 μM	LD ₅₀ HEK 293 cells (μM)
4	10	27	23	58
11	6	20	0	61
12	4	n.i. ^a	0	68
13	8	35	12	80
17	25	30	6	86
18	39	30	0	> 100
19	3	n.d. ^b	n.d. ^b	94
20	13	n.d. ^b	n.d. ^b	> 100

^ano inhibition; ^bnot determined.

Antiretroviral Activity in NNRTI Resistant HIV-1 Strains

Based on the docking study, the binding mode of our new NNRTIs could be advantageous regarding the resistance issue. The numerous interactions between our ligands and the NNRTI binding pocket, especially those with the highly conserved amino acids, should only be moderately affected by the

single site mutations that result from using other NNRTIs and are responsible for resistance.^{9,10,30} To verify this point and to get more insight into the binding mode of our compounds, we tested the antiviral activity of compounds **11**, **18** and **19** against the HIV-1 wild-type (WT) NL4-3 and a panel of strains with multiple resistance mutations to clinically used NNRTIs in a TZM-bl cell line based phenotypic assay (Table 4).

Table 4. Antiretroviral Activity of **11**, **18**, **19** and Reference NNRTIs against HIV-1 WT (114) and NNRTIs-Resistant Strains (12237, 12235, 12231, 12229).

Compound	IC ₅₀ (μM)	Fold change in susceptibility ^a (biological ^b or clinical ^c cut-off)			
	114 ^d NL4-3 (WT)	12237 ^d (V106I, Y181C, G190A, H221Y) ^e	12235 ^d (A98G, K101E, Y181C, G190A) ^e	12231 ^d (K103N, V179F, Y181C) ^e	12229 ^d (L100I, K103N, H221Y) ^e
11	5	1	3	> 4	> 4
18	5	1.5	3.5	> 4	> 4
19	15	> 1.5	1	> 1.5	> 1.5
NVP	0.1 ^f	> 200 (4.5) ^b	> 200 (4.5) ^b	> 200 (4.5) ^b	> 200 (4.5) ^b
EFV	0.002 ^f	26 (3) ^b	> 200 (3) ^b	90 (3) ^b	> 200 (3) ^b
ETR	0.005 ^f	6.0 (2.9) ^c	15 (2.9) ^c	8.8 (2.9) ^c	6.8 (2.9) ^c
RPV	0.0009 ^f	3.5 (2) ^b	22 (2) ^b	2.3 (2) ^b	6.3 (2) ^b

^aResistant virus IC₅₀/WT virus IC₅₀ ratio calculated with the Phenosense assay; ^bThe biological cut-off was determined by *in vitro* analysis of multiple viral variants not exposed to the drug and defined as the mean fold-change plus two standard deviations with respect to the reference viral strain. It is used when a clinical cut-off has not been established; ^cThe clinical cut-off was determined by statistical analysis of clinical data and is defined as the fold-change value corresponding to loss of drug activity *in vivo*; ^dID of viruses are referred to the NIH AIDS Reagent Program catalogue number; ^eThe NNRTIs resistance mutations; ^fIC₅₀ values against WT were previously determined³⁹; EFV = efavirenz, ETR = etravirine, RPV = rilpivirine.

Our results reveal that the tested compounds show good activity against the WT (IC₅₀s 5–15 μM) as well as against the mutants 12237 and 12235. In contrast, they are unable to halt the replication of 12231 and 12229 strains. At the same time, the reference drugs NVP, EFV and ETR show a dramatic loss of potency against all resistant mutants.

These data indicate that our compounds are still able to bind to and to inhibit the RTs with mutations K101E, V106I, Y181C and G190A, which confer high-level resistance against NNRTIs.^{10,30} This can on the one side be attributed to the presence of essential contacts between our ligands and the amino

acid residues of high fitness costs such as Leu100, Phe227, and Trp229. On the other side, due to the conformational flexibility of our compounds they can easily adopt to the steric changes in the binding site of the mutated proteins. Interestingly, the K103N mutation seems to have a negative effect on our compounds' RT inhibition and antiretroviral activity. This result does not contradict our predicted binding mode, since this mutation affects the pocket entrance.⁴⁰ In addition, the L100I mutation may impair the binding to RT.

These findings are consistent with the predicted binding mode of our new NNRTIs and thus further confirm their binding site. Moreover, the fact that no cross-resistance was observed in some NNRTI-resistant strains is an important advantage over the 1st (NVP and EFV) and 2nd generation (ETR and RPV) NNRTIs.

Finally, we performed a docking study for the most active compound **18** (Figure 3). Comparing to the binding of **11**, the eastern part of the molecules binds identically to the protein. Unexpectedly, in the western part a slight change was observed as the newly introduced methanesulfonamido group leads to CH- π interaction with the highly conserved Trp229. As a consequence of this, the N-phenyl ring is slightly shifted downward away from Trp229. Moreover, an atypical hydrogen bond was identified between the conserved Phe227 (as donor) and the 3,4-dichlorophenyl motif (as acceptor). Furthermore, no π - π interaction was observed between Tyr181 and the N-phenyl moiety (centroid-centroid distance > 4 Å).





Figure 3. Docking pose of **18** in the NNRTI binding site.

Chemistry


Synthesis of the 5-aryl-2-ureidothiophene-3-carboxylic acids was accomplished through a straightforward procedure starting with 3,4-dichlorophenylacetic acid **21** (Scheme 1). Reduction with LiAlH_4 followed by mild oxidation of the produced alcohol **22** using PCC delivered the arylacetaldehyde **23** in a good yield. Gewald reaction of **23** with ethyl cyanoacetate and elemental sulfur under basic conditions in a one-pot reaction afforded the 2-aminothiophene-3-carboxylate **24**.²² The ester was saponified to the corresponding acid **25**, which was treated with BTC to produce the 6-arylthiaisatoic anhydride **26**. Synthesis was finalized via coupling of **26** and the appropriate amine in water/TEA (2:1) mixture at room temperature followed by acidic workup to yield the 5-aryl-2-ureidothiophene-3-carboxylic acids **9–20**.

Scheme 1. Synthesis of the 2-ureidothiophene-3-carboxylic acids **9–20**^a



^aReagents and conditions: (a) LiAlH_4 , THF, reflux, 2 h; (b) PCC, DCM, rt, 2 h; (c) $1/8 \text{ S}_8$, $\text{NCCH}_2\text{COOEt}$, TEA, ethanol, reflux, 12 h; (d) KOH, MeOH/ H_2O , reflux, 4 h; (e) BTC, THF, rt, 2 h; (f) $\text{R}^1\text{R}^2\text{NH}$, $\text{H}_2\text{O}/\text{TEA}$, rt, 2 h.


The *N*-monosubstituted-*p*-phenylenediamines were prepared from *p*-nitroaniline **27** keeping the nitro moiety as a hidden protected amino group (Scheme 2). Reaction of **27** with acyl chlorides or sulfonyl chlorides in the presence of pyridine yielded the corresponding amides or sulfonamides, respectively. The nitro derivatives were reduced by iron/ammonium chloride mixture to afford the corresponding amines in excellent yields.

Scheme 2. Synthesis of the intermediate aromatic amines^a

^aReagents and conditions: (a) Fe/NH₄Cl, EtOH, reflux, 1 h; (b) RCOCl or RSO₂Cl, pyridine/DCM, rt, 12 h; (c) 1,2,4-triazole, K₂CO₃/DMF, 70 °C, 1 h.

It is noteworthy that TEA is crucial for formation of the desired ureidothiophene carboxylic acids. Modification of the previous procedures that did not employ TEA in the coupling step^{21,22} was necessary to enhance the reaction regioselectivity. Since the utilized anilines in this work are weak nucleophiles, the coupling reaction using *p*-anisidine for example in absence of TEA afforded a mixture of the amide **42** and the ureidocarboxylic acid **13** in nearly 1:1 ratio as indicated from the ¹H NMR spectrum (Figure S3). In contrast, running the same reaction in presence of TEA produced exclusively the ureidothiophene carboxylic acid **13** in 100% regioselectivity (Scheme 3). Moreover, we found that the loss of amine regioselectivity and reactivity is directly proportional to the electron deficiency of the substituted aniline, i.e. no ureidothiophene product could be obtained from the reaction of **26** with *p*-nitroaniline **27** even when TEA was applied.

Scheme 3. Reaction of **26** with *p*-anisidine in presence and absence of TEA.



CONCLUSION

In this work we discovered and developed 2-ureidothiophene-3-carboxylic acids as dual bacterial RNAP and HIV-1 RT inhibitors for the treatment of MRSA/HIV-1 co-infections. This development was based on an unprecedented exploitation of the functional and structural similarities between the RNAP “switch region” and the NNRTI allosteric binding site. First, we identified the privileged structure for RT inhibition by screening four regioisomeric classes of “switch region” binding RNAP inhibitors. Next, we explored the steric volume allowed in the NNRTI binding pocket through enlarging the bulkiness of the ureido moiety. Finally, we applied a structure-based design strategy for hit optimization. We were able to improve the RT inhibitory activity, in parallel with enhancing, or at least maintaining, the activity against RNAP. SAR studies revealed the importance of hydrophilic non-bulky substituents at the ureido side chain for RT inhibition. A MoA investigation revealed a non-competitive inhibition mechanism of our compounds, which is typical for NNRTIs. Interestingly, the compounds seem to act through a new mechanism via closing of the RT clamp. The new RNAP/RT inhibitors displayed high potency against *S. aureus* as well as *in cellulo* antiretroviral activity accompanied by marginal or no cytotoxicity. Furthermore, these compounds were active against NNRTI-resistant strains. Thus, our work establishes the basis for the development of a single compound therapy not only against MRSA/HIV co-infection, but also against other challenging coinfections of major public health concern especially Mtb/HIV coinfection.

EXPERIMENTAL SECTION

Materials and Methods

Starting materials and solvents were purchased from commercial suppliers, and used without further purification. All chemical yields refer to purified compounds, and were not optimized. Reaction progress was monitored using TLC Silica gel 60 F₂₅₄ aluminium sheets, and visualization was accomplished by UV at 254 nm. Flash chromatography was performed using silica gel 60 Å (40–63 μm). Preparative RP-HPLC was carried out on a Waters Corporation setup contains a 2767 sample manager, a 2545 binary gradient module, a 2998 PDA detector and a 3100 electron spray mass spectrometer. Purification was performed using a Waters XBridge column (C18, 150 × 19 mm, 5 μm), a binary solvent system A and B (A = water with 0.1% formic acid; B = MeCN with 0.1% formic acid) as eluent, a flow rate of 20 mL/min and a gradient of 60% to 95% B in 8 min were applied. NMR spectra were recorded either on Bruker DRX-500 (¹H, 500 MHz; ¹³C, 126 MHz), or Bruker Fourier 300 (¹H, 300 MHz; ¹³C, 75 MHz) spectrometer at 300 K. Chemical shifts were recorded as δ values in ppm units by reference to the hydrogenated residues of deuterated solvent as internal standard (CDCl₃: δ = 7.27, 77.00; DMSO-d₆: δ = 2.50, 39.51). Splitting patterns describe apparent multiplicities and are designated as s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet). Coupling constants (*J*) are given in Hertz (Hz). Weak or coalesced signals were elucidated by Heteronuclear Multiple Quantum Coherence (HMQC) and Heteronuclear Multiple Bond Coherence (HMBC) 2D-NMR techniques. Purity of all compounds used in biological assays was ≥ 95% as measured by LC/MS Finnigan Surveyor MSQ Plus (Thermo Fisher Scientific, Dreieich, Germany). The system consists of LC pump, autosampler, PDA detector, and single-quadrupole MS detector, as well as the standard software Xcalibur for operation. RP C18 Nucleodur 100-5 (125 × 3 mm) column (Macherey-Nagel GmbH, Dühren, Germany) was used as stationary phase, and a binary solvent system A and B (A = water with 0.1% TFA; B = MeCN with 0.1% TFA) was used as mobile phase. In a gradient run the percentage of B was increased from an initial concentration of 0% at 0 min to 100% at 15 min and kept at 100% for 5 min. The injection volume was 10 μL and the flow rate was set to 800 μL/min. MS (ESI) analysis was carried out at a spray voltage of 3800 V, a capillary

temperature of 350 °C and a source CID of 10 V. Spectra were acquired in positive mode from 100 to 1000 m/z and at 254 nm for UV tracing.

General procedure for synthesis of 5-(3,4-dichlorophenyl)-2-[3-(4-(un)substitutedphenyl)ureido]thiophene-3-carboxylic acids 11–20

To a stirred suspension of the thiaisatoic anhydride **26** (150 mg, 0.48 mmol) in a mixture of water (6 mL) and TEA (1 mL), the appropriate amine (1.0 mmol) in TEA (2 mL) was added. The reaction mixture was stirred at rt overnight, then poured on ice-cooled 2 N HCl (40 mL), and extracted with EtOAc/THF (1:1, 40 mL). The organic layer was washed with cold 2 N HCl/brine (1:1, 2 × 40 mL), dried over anhydrous MgSO₄, and concentrated *in vacuo*. The obtained crude material was suspended in *n*-hexane/EtOAc (4:1, 50 mL), stirred in a water bath at 40 °C for 10 min, cooled, and collected by filtration.

5-(3,4-Dichlorophenyl)-2-(3-phenylureido)thiophene-3-carboxylic acid (11)

Yield 90%; beige solid; ¹H NMR (500 MHz, DMSO-d₆) δ 13.02 (br s, 1H), 10.61 (br s, 1H), 10.36 (br s, 1H), 7.88 (d, *J* = 2.0 Hz, 1H), 7.63 (s, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.58 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.52 (m, 2H), 7.33 (m, 2H), 7.04 (m, 1H); ¹³C NMR (126 MHz, DMSO-d₆) δ 165.80, 150.98, 150.15, 138.86, 134.31, 131.87, 131.07, 129.07, 128.94 (2C), 127.72, 126.10, 124.70, 122.77, 122.27, 118.49 (2C), 112.36; m/z (ESI+) 407 [M + H]⁺; t_R = 14.49 min.

5-(3,4-Dichlorophenyl)-2-(3-(4-fluorophenyl)ureido)thiophene-3-carboxylic acid (12)

Yield 82%; grey solid; ¹H NMR (300 MHz, DMSO-d₆) δ 13.04 (br s, 1H), 10.60 (br s, 1H), 10.39 (br s, 1H), 7.88 (d, *J* = 1.5 Hz, 1H), 7.63 (s, 1H), 7.59 (m, 2H), 7.51 (m, 2H), 7.17 (m, 2H); ¹³C NMR (75 MHz, DMSO-d₆) δ 165.81, 157.84 (d, *J* = 239.2 Hz, 1C), 151.00, 150.12, 135.17 (d, *J* = 2.2 Hz, 1C), 134.28, 131.86, 131.07, 129.08, 127.75, 126.10, 124.70, 122.25, 120.27 (d, *J* = 7.5 Hz, 2C), 115.50 (d, *J* = 22.4 Hz, 2C), 112.37; m/z (ESI+) 424 [M]⁺; t_R = 14.96 min.

5-(3,4-Dichlorophenyl)-2-(3-(4-methoxyphenyl)ureido)thiophene-3-carboxylic acid (13)

Yield 86%; beige solid; ¹H NMR (300 MHz, DMSO-d₆) δ 12.66 (br s, 1H), 10.56 (br s, 1H), 10.16 (br s, 1H), 7.88 (d, *J* = 1.0 Hz, 1H), 7.62 (s, 1H), 7.57 (m, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 6.91 (d, *J* = 8.8 Hz, 2H), 3.73 (s, 3H); ¹³C NMR (75 MHz, DMSO-d₆) δ 165.86, 155.11, 151.04, 150.40, 134.37,

131.86, 131.78, 131.08, 129.01, 127.52, 126.07, 124.69, 122.27, 120.31 (2C), 114.15 (2C), 112.16, 55.20; m/z (ESI+) 437 [M + H]⁺; t_R = 14.36 min.

2-(3-(4-Aminophenyl)ureido)-5-(3,4-dichlorophenyl)thiophene-3-carboxylic acid (14)

Yield 80%; pink solid; ¹H NMR (300 MHz, DMSO-d₆) δ 11.88 (br s, 1H), 10.72 (br s, 1H), 9.83 (br s, 1H), 7.84 (d, *J* = 1.0 Hz, 1H), 7.57 (m, 3H), 7.14 (d, *J* = 8.6 Hz, 2H), 6.54 (d, *J* = 8.6 Hz, 2H), 3.43 (br s, 2H); ¹³C NMR (75 MHz, DMSO-d₆) δ 166.19, 151.23, 150.33, 144.86, 134.61, 131.81, 131.06, 128.75, 127.51, 126.94, 125.90, 124.55, 122.55, 120.92 (2C), 114.12 (2C), 112.83; m/z (ESI+) 421 [M]⁺; t_R = 9.78 min.

2-(3-(4-Acetamidophenyl)ureido)-5-(3,4-dichlorophenyl)thiophene-3-carboxylic acid (15)

Yield 90%; beige solid; ¹H NMR (500 MHz, DMSO-d₆) δ 13.04 (br s, 1H), 10.58 (br s, 1H), 10.27 (br s, 1H), 9.87 (br s, 1H), 7.89 (d, *J* = 1.9 Hz, 1H), 7.63 (s, 1H), 7.61 (d, *J* = 8.5 Hz, 1H), 7.58 (dd, *J* = 8.5, 1.9 Hz, 1H), 7.53 (d, *J* = 9.1 Hz, 2H), 7.42 (d, *J* = 9.1 Hz, 2H), 2.02 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 167.91, 165.79, 150.94, 150.27, 134.60, 134.34, 133.93, 131.85, 131.07, 129.02, 127.60, 126.09, 124.70, 122.26, 119.62 (2C), 118.95 (2C), 112.20, 23.87; m/z (ESI+) 464 [M + H]⁺; t_R = 17.40 min.

2-(3-(4-(2-(1*H*-1,2,4-Triazol-1-yl)acetamido)phenyl)ureido)-5-(3,4-dichlorophenyl)thiophene-3-carboxylic acid (16)

Yield 65%; pale grey solid; ¹H NMR (500 MHz, DMSO-d₆) δ 13.02 (br s, 1H), 10.94 (br s, 1H), 10.61 (br s, 1H), 10.52 (br s, 1H), 8.65 (s, 1H), 8.04 (s, 1H), 7.89 (d, *J* = 1.9 Hz, 1H), 7.63 (s, 1H), 7.61 (d, *J* = 8.5 Hz, 1H), 7.60 (d, *J* = 9.1 Hz, 2H), 7.58 (dd, *J* = 8.5, 1.9 Hz, 1H), 7.47 (d, *J* = 9.1 Hz, 2H), 5.21 (s, 2H); ¹³C NMR (126 MHz, DMSO-d₆) δ 165.66, 164.11, 150.99, 150.91, 150.13, 145.44, 134.60, 134.35, 133.78, 131.84, 131.09, 129.00, 127.60, 126.08, 124.72, 122.30, 119.83 (2C), 118.94 (2C), 112.35, 51.82; m/z (ESI+) 531 [M + H]⁺; t_R = 17.10 min.

5-(3,4-Dichlorophenyl)-2-(3-(4-((methoxycarbonyl)amino)phenyl)ureido)thiophene-3-carboxylic acid (17)

Yield 65%; white solid; ¹H NMR (500 MHz, DMSO-d₆) δ 13.01 (br s, 1H), 10.60 (br s, 1H), 10.25 (br s, 1H), 9.55 (br s, 1H), 7.87 (d, *J* = 1.9 Hz, 1H), 7.62 (s, 1H), 7.60 (d, *J* = 8.2 Hz, 1H), 7.57 (dd, *J* = 8.2, 1.9 Hz, 1H), 7.42 (d, *J* = 8.5 Hz, 2H), 7.40 (d, *J* = 8.5 Hz, 2H), 3.65 (s, 3H); ¹³C NMR (126 MHz,

DMSO-d₆) δ 165.87, 154.09, 151.01, 150.28, 134.39, 134.36, 133.59, 131.89, 131.11, 129.05, 127.60, 126.10, 124.72, 122.31, 119.23 (2C), 118.91 (2C), 112.34, 51.57; m/z (ESI+) 480 [M + H]⁺; t_R = 13.46 min.

5-(3,4-Dichlorophenyl)-2-(3-(4-(methylsulfonamido)phenyl)ureido)thiophene-3-carboxylic acid (18)

Yield 70%; white crystals; ¹H NMR (300 MHz, DMSO-d₆) δ 13.01 (br s, 1H), 10.60 (br s, 1H), 10.35 (br s, 1H), 9.54 (br s, 1H), 7.88 (d, *J* = 1.0 Hz, 1H), 7.62 (s, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.56 (dd, *J* = 8.0, 1.0 Hz, 1H), 7.48 (d, *J* = 8.6 Hz, 2H), 7.19 (d, *J* = 8.6 Hz, 2H), 2.94 (s, 3H); ¹³C NMR (75 MHz, DMSO-d₆) δ 165.82, 150.97, 150.16, 135.49, 134.31, 133.08, 131.88, 131.08, 129.07, 127.71, 126.10, 124.72, 122.27, 121.73 (2C), 119.45 (2C), 112.36, 38.95; m/z (ESI+) 499 [M]⁺; t_R = 12.86 min.

5-(3,4-Dichlorophenyl)-2-(3-(4-(phenylsulfonamido)phenyl)ureido)thiophene-3-carboxylic acid (19)

Yield 88%; reddish solid; ¹H NMR (500 MHz, DMSO-d₆) δ 13.04 (br s, 1H), 10.56 (br s, 1H), 10.29 (br s, 1H), 10.09 (br s, 1H), 7.88 (d, *J* = 2.2 Hz, 1H), 7.72 (m, 2H), 7.62 (s, 1H), 7.60 (m, 2H), 7.55 (m, 3H), 7.36 (d, *J* = 9.1 Hz, 2H), 7.03 (d, *J* = 9.1 Hz, 2H); ¹³C NMR (126 MHz, DMSO-d₆) δ 165.76, 150.87, 150.08, 139.46, 135.56, 134.28, 132.77, 132.27, 131.85, 131.07, 129.16 (2C), 129.06, 127.69, 126.63 (2C), 126.10, 124.70, 122.26, 121.88 (2C), 119.20 (2C), 112.33; m/z (ESI+) 561 [M]⁺; t_R = 17.26 min.

5-(3,4-Dichlorophenyl)-2-(3-(4-((*N,N*-dimethylsulfamoyl)amino)phenyl)ureido)thiophene-3-carboxylic acid (20)

Yield 79%; beige solid; ¹H NMR (500 MHz, DMSO-d₆) δ 13.06 (br s, 1H), 10.59 (br s, 1H), 10.31 (br s, 1H), 9.72 (br s, 1H), 7.89 (d, *J* = 2.2 Hz, 1H), 7.63 (s, 1H), 7.61 (d, *J* = 8.2 Hz, 1H), 7.58 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.44 (d, *J* = 9.1 Hz, 2H), 7.18 (d, *J* = 9.1 Hz, 2H), 2.69 (s, 6H); ¹³C NMR (126 MHz, DMSO-d₆) δ 165.78, 150.95, 150.18, 134.78, 134.31, 133.45, 131.85, 131.07, 129.05, 127.66, 126.10, 124.70, 122.24, 120.95 (2C), 119.32 (2C), 112.27, 37.75 (2C); m/z (ESI+) 529 [M + H]⁺; t_R = 17.20 min.

1
2
3 Experimental procedures for the synthesis of all other target compounds and necessary precursors
4 together with their characterization and NMR spectra are described in details in the Supporting
5 Information.
6
7

8
9 **Computational Chemistry** All computational work was performed using Molecular Operating
10 Environment (MOE) version 2015.10, Chemical Computing Group Inc., 1010 Sherbrooke St. West,
11 Suite 910, Montreal, Quebec, H3A 2R7, Canada.
12
13

14
15 **Similarity Analysis** A database containing compounds **2** and **4** was created and the fingerprint
16 piDAPH4 (pi-donor-acceptor-polar-hydrophobe-4 point pharmacophore) was calculated for both
17 entries. Compound **4** was selected as a reference structure and sent to MOE window. In the database
18 viewer window, similarity search was performed by setting the fingerprint system to piDAPH4, and
19 using the similarity metric Tanimoto coefficient (T_C) to measure similarity between molecules. T_C
20 values range from 0 (no similarity) to 1 (complete similarity).
21
22

23
24 **Preparation of Ligands and Protein Structure for Docking** In the database viewer window,
25 compounds **11** and **18** were selected and washed via compute | molecule | wash command.
26 Deprotonation of strong acids and protonation of strong bases options were checked in the wash panel.
27 X-ray crystal structure of the HIV-1 RT in complex with NVP (PDB code 1VRT)¹⁴ was used to
28 perform the molecular docking study. Potential was setup to Amber10:EHT for force field and R-field
29 for solvation. Addition of hydrogen atoms and removal of water molecules were performed via LigX
30 module.
31
32

33
34 **Ligand–Receptor Docking** Using the induced fit docking protocol, the binding site was set to dummy
35 atoms which were identified by the site finder mode, and the amino acid residues were chosen where
36 nevirapine binds in the RT allosteric binding site. Docking placement was triangle matcher with rotate
37 bonds option. The 1st rescoring was ASE with force field refinement, and the 2nd rescoring was alpha
38 HB.
39
40

41
42 **QSAR Analysis** A database containing compounds **11–20** was created, and each structure was
43 subjected to energy minimization up to a gradient 0.01 kcal/mol/Å using the MMFF94x force field and
44 distance solvation model. In the database viewer window, molecular descriptors were calculated for all
45
46
47
48
49
50
51

entries via activating the compute panel, choosing descriptors calculate option (Table S1). The QSAR model was computed using partial least squares (PLS) method.

Binding Measurements were performed at 20 °C using a Fluoromax 4 spectrofluorometer (Jobin-Yvon Horiba) by monitoring the increase of FRET efficiency, E_{FRET} , associated to the formation of the complex between Alexa488-labeled RT and TAMRA-labeled p/t duplexes. The FRET efficiency, calculated by $E_{FRET} = 1 - I_{DA}/I_D$ (where I_D and I_{DA} are the intensities of the Alexa 488 donor in the absence and in the presence of the TAMRA acceptor, respectively), was then plotted as a function of the total concentration of the labeled oligonucleotide (ODN) and fitted with a rewritten Scatchard equation considering a model with a single binding site

$$E_{FRET} = E_F \left\{ \frac{K_d + M_{tot} + L_{tot} - \sqrt{[K_d + M_{tot} + L_{tot}]^2 - 4M_{tot}L_{tot}}}{2K_d L_{tot}} \right\} \quad (3)$$

where E_F corresponds to the FRET efficiency at saturation, L_{tot} and M_{tot} are respectively the concentration of RT and p/t duplex and K_d is the dissociation constant. Fit parameters were recovered from non-linear fits of eq 3 to the experimental datasets using a non-linear least-squares method and the Levenberg–Marquardt algorithm in the Origin 8 software.

RT Inhibitory Activity of Compounds was determined as described previously.²⁴ All measurements were carried out using a 23-mer (5'- CAG CAG TAC AAA TGG CAG TAT TC) DNA-primer labeled at the T19 position with Cyanine 5 (Cy5), annealed to a 63-mer (3'-TGT CGT CAT GTT TAC CGT CAT AAG TAG GTG TTA CTA GTC CGA TTT CCC CTA GTC CGA CCC ATG)-template labeled at the T2 position with TAMRA. Both TAMRA and Cy5 were covalently attached via a C6 amino link to their respective T residues in the primer and the template. Primer and template ODN were annealed by heating equimolar amounts in buffer at 90 °C for 2 min, followed by cooling to room temperature over several hours. All measurements were performed at 20 °C using a Fluoromax 4 spectrofluorometer (Jobin-Yvon Horiba) or a stopped-flow apparatus (SF3, Biologics). The FRET donor, TAMRA, was excited at 540 nm, and its emission was recorded at 580 nm. Nucleotide incorporation kinetics was triggered by addition of dNTPs in excess to a pre-incubated mixture of

HIV-RT and p/t duplexes at equimolar concentrations. The annealing kinetic traces were adequately fitted using

$$I(t) = I_F - (I_F - I_0)(ae^{(-k_{obs1}(t-t_0))} - (1-a)e^{(-k_{obs2}(t-t_0))}) \quad (4)$$

where t_0 is the dead time, $k_{obs1,2}$ are the observed kinetic rate constants, a is the amplitude of the fast component, and I_0 and I_F are the fluorescence intensities before dNTPs addition and at completion of the reaction, respectively. The I_0 value was obtained from the steady-state fluorescence spectrum of the doubly labeled p/t duplex in the presence of RT and was thus fixed. All fitting procedures were carried out with Origin™ 8.6 software using nonlinear, least-square methods and the Levenberg-Marquardt algorithm.

HeLa Infectivity and Cytotoxicity Assay The infectivity assay was based on infection of HeLa cells by a third-generation of pseudoparticles³⁸ mimicking the early steps of the HIV-1 virus cycle. The pseudoparticles contain Gag, Gag-pol, RRE and Vesicular Stomatitis Virus (VSV)-G proteins and a RNA encoding reporter gene for luciferase. The luciferase sequence is incorporated in the host genome during infection by pseudoparticles which give the possibility to quantify infection. A total of 5×10^3 HeLa cells/well were seeded in 96 wells plate 24 h prior to infection in Dulbecco's Modified Eagle Medium (Life Technologies) (DMEM) complemented with 10% fetal bovine serum, penicillin (100 UI/mL), and streptomycin (100 μ g/mL) and incubated in a 5% CO₂ incubator. After medium removal, 50 μ L of two times concentrated solutions of compounds were added 30 min before adding 50 μ L of pseudoparticles, which can infect 50% of cells in presence of polybrene (8 μ g/mL). Cells were washed, 24 h after infection, one time by PBS and lysed with Passive Lysis Buffer (Promega) supplemented with 0.5% Triton X-100 for 30 min under constant shaking. Luciferase activity was measured for 10 s in a luminometer (Tristar 2 Multimode reader LB 942, Berthold) after injection of 50 μ L of luciferine reagent (25 mM Tricine Buffer pH = 7.8, 0.5 mM EDTA pH 7.9, 5 mM MgSO₄, 5 mM DTT, 0.5 mM ATP, 1.65 mM D-luciferin sodium salt and 0.325 mM Coenzyme A Sodium Salt hydrate).

For each compound, we used as a control, cells incubated with DMEM containing the same percentage of DMSO (maximum 0.5% v/v) as the solutions with the tested molecules. For each tested

molecule and concentration, we calculated the percentage of inhibition (*%inh*) with the following equation

$$\%inh \text{ or } \%cyt = \frac{(\text{Control value}) - (\text{Sample value})}{(\text{Control value})} \times 100 \quad (5)$$

Each concentration of tested compound was tested in sextuplicate. To determine the IC₅₀ values, we plotted the percentage of inhibition against the inhibitor concentration (*I*) and fitted it with a modified version of the dose-response effect equation

$$y = \frac{A_1 + (A_2 - A_1)}{1 + 10^{(\log(I_{50}) - \log(I)) * p}} \quad (6)$$

where, *A*₁ and *A*₂ represent the percentage of inhibition in the absence (0%) and in saturating concentrations (100%) of inhibitor, respectively. *I*₅₀ represents the half maximal inhibitory concentration and *p* denotes hill coefficient.

Cytotoxicity of compounds was quantified by the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide).⁴¹ Another plate was prepared in the same conditions as for the infectivity assay. 24 h after infection, medium was replaced by 110 μL of a mix containing 100 μL of DMEM and 10 μL of 12 mM MTT solution in PBS and cells were incubated during 4 h. In order to dissolve the insoluble purple formazan reduced by living cells, 85 μL of the mix was replaced by 50 μL of DMSO and gently shaken for 10 min. The absorbance was then measured at 540 nm in a spectrophotometer (Safas Monaco) and converted in percentage of cytotoxicity (*% cyt*), in reference to the control (DMEM + DMSO).

Antiretroviral Assay against HIV-1 WT and NNRTIs-Resistant Strains The WT virus and the NNRTIs-resistant strains were obtained through the NIH AIDS Reagent Program (ARP, www.aidsreagent.org) and have been already characterized by the Phenosense Assay (Monogram Biosciences), considered as the reference assay for phenotypic investigation of HIV drug resistance due to its large application in clinical trials. The infectious clones were firstly transfected in 293LX cells and then expanded in MT-2 cells. The antiretroviral assay was determined in a TZM-bl cell line based phenotypic assay. TZM-bl cells are characterized by the presence of the luciferase and β-galactosidase reporter genes integrated in the cell genome under control of the HIV-1 LTR promoter.

1
2
3 Expression of the reporter genes is regulated by the viral Tat protein, which is produced following
4 transcription of the integrated provirus. TZM-bl cells were seeded at a concentration of 30,000
5 cells/well in a 96-well plate using DMEM medium without fetal bovine serum (FBS) and infected
6 with the viruses in the presence of 20, 10, 5 and 1 μM of each compound. After 48 hours, cells were
7 lysed by adding 40 μL of Glo Lysis Buffer (Promega) to each well for 5 minutes, then 40 μL of
8 Bright-Glo Luciferase Reagent (Promega) were added to each well for counting relative luminescence
9 units (RLU) using the Glo-Max Multi Detection System (Promega). RLU values from each well were
10 elaborated using the GraphPad v5.0 software to calculate the IC_{50} of each compound.

11
12
13 **RNAP Inhibition, Antibacterial Activity and Cytotoxicity** Transcription inhibition assay,
14 determination of IC_{50} values, minimal inhibitory concentrations (MICs) and cytotoxicity in HEK 293
15 cells were performed as described previously.²²

26 ASSOCIATED CONTENT

27 Supporting Information

28 This material is available free of charge via the Internet at <http://pubs.acs.org>.

29 Experimental procedures and analytical data for all other compounds; Substituent constants and
30 molecular descriptors of compounds **11–20**; Binding and mechanistic studies of the compounds; ^1H
31 and ^{13}C NMR spectra (PDF)

32 Molecular formula strings (CSV)

33 AUTHOR INFORMATION

34 Corresponding Author

35 * E-mail: rolf.hartmann@helmholtz-hzi.de, Phone: +(49) 681 302 70300.

36 ACKNOWLEDGMENTS

37 The authors thank Jeannine Jung for technical assistance. Walid A. M. Elgaher gratefully
38 acknowledges a scholarship from the German Academic Exchange Service (DAAD). Kamal K.
39 Sharma, Francesco Saladini, Manuel Pires and part of this work were supported by the European
40 Project THINPAD “Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug
41 Resistance” [FP7-Grant Agreement 601969 to Y.M.].

ABREVIATIONS USED

ART, antiretroviral therapy; AZT-TP, azidothymidine triphosphate; BTC, bis(trichloromethyl) carbonate; DMEM, Dulbecco's modified Eagle's medium; dNTPs, deoxyribonucleotides; EFV, efavirenz; ETR, etravirine; FBS, fetal bovine serum; HAART, highly active antiretroviral therapy; LLE, ligand-lipophilicity efficiency; MoA, mode of action; Mtb, *Mycobacterium tuberculosis*; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NVP, nevirapine; ODN, oligonucleotide; piDAPH4, pi-donor-acceptor-polar-hydrophobe-4 point pharmacophore; p/t, primer/template; RLU, relative luminescence units; RNAP, RNA polymerase; RPV, rilpivirine; RT, reverse transcriptase; TAMRA, carboxytetramethylrhodamine; T_C , Tanimoto coefficient; TEA, triethylamine.

REFERENCES

- (1) WHO. HIV/AIDS, Fact sheet N°360, 2015. <http://www.who.int/mediacentre/factsheets/fs360/en/>.
- (2) Bonnet, M. M. B.; Pinoges, L. L. P.; Varaine, F. F. V.; Oberhauser, B. B. O.; O'Brien, D. D. O.; Kebede, Y. Y. K.; Hewison, C. C. H.; Zachariah, R. R. Z.; Ferradini, L. L. F. Tuberculosis after HAART Initiation in HIV-Positive Patients from Five Countries with a High Tuberculosis Burden. *AIDS (London, U.K.)* **2006**, *20*, 1275–1279.
- (3) Mathews, W. C.; Caperna, J. C.; Barber, R. E.; Torriani, F. J.; Miller, L. G.; May, S.; McCutchan, J. A. Incidence of and Risk Factors for Clinically Significant Methicillin-Resistant *Staphylococcus aureus* Infection in a Cohort of HIV-Infected Adults. *J. Acquir. Immune Defic. Syndr.* **2005**, *40*, 155–160.
- (4) Hidron, A. I.; Kempker, R.; Moanna, A.; Rimland, D. Methicillin-Resistant *Staphylococcus aureus* in HIV-Infected Patients. *Infect. Drug Resist.* **2010**, *3*, 73–86.
- (5) Crum-Cianflone, N. F.; Burgi, A. A.; Hale, B. R. Increasing Rates of Community-Acquired Methicillin-Resistant *Staphylococcus aureus* Infections among HIV-Infected Persons. *Int. J. STD AIDS* **2007**, *18*, 521–526.
- (6) Martin, J. N.; Rose, D. A.; Hadley, W. K.; Perdreau-Remington, F.; Lam, P. K.; Gerberding, J. L. Emergence of Trimethoprim-Sulfamethoxazole Resistance in the AIDS Era. *J. Infect. Dis.* **1999**, *180*, 1809–1818.

- 1
2
3 (7) Diep, B. A.; Chambers, H. F.; Graber, C. J.; Szumowski, J. D.; Miller, L. G.; Han, L. L.; Chen, J.
4 H.; Lin, F.; Lin, J.; Phan, T. H.; Carleton, H. A.; McDougal, L. K.; Tenover, F. C.; Cohen, D. E.;
5 Mayer, K. H.; Sensabaugh, G. F.; Perdreau-Remington, F. Emergence of Multidrug-Resistant,
6 Community-Associated, Methicillin-Resistant *Staphylococcus aureus* Clone USA300 in Men Who
7 Have Sex with Men. *Ann. Intern. Med.* **2008**, *148*, 249–257.
- 8
9 (8) Mansky, L. M. HIV Mutagenesis and the Evolution of Antiretroviral Drug Resistance. *Drug*
10 *Resist. Update.* **2002**, *5*, 219–223.
- 11
12 (9) Asahchop, E. L.; Wainberg, M. A.; Sloan, R. D.; Tremblay, C. L. Antiviral Drug Resistance and
13 the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors. *Antimicrob. Agents*
14 *Chemother.* **2012**, *56*, 5000–5008.
- 15
16 (10) Tang, M. W.; Shafer, R. W. HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical
17 Applications. *Drugs* **2012**, *72*, e1–e25.
- 18
19 (11) Dejesus, E.; Young, B.; Morales-Ramirez, J. O.; Sloan, L.; Ward, D. J.; Flaherty, J. F.;
20 Ebrahimi, R.; Maa, J.-F.; Reilly, K.; Ecker, J.; McColl, D.; Seekins, D.; Farajallah, A. Simplification
21 of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and
22 Tenofovir Disoproxil Fumarate versus Unmodified Antiretroviral Therapy in Virologically Suppressed
23 HIV-1-Infected Patients. *J. Acquir. Immune Defic. Syndr.* **2009**, *51*, 163–174.
- 24
25 (12) Piscitelli, S. C.; Gallicano, K. D. Interactions among Drugs for HIV and Opportunistic
26 Infections. *N. Engl. J. Med.* **2001**, *344*, 984–996.
- 27
28 (13) Krentz, H. B.; Gill, M. J. Increased Costs of HIV Care Associated with Aging in an HIV-
29 Infected Population. *HIV Med.* **2015**, *16*, 38–47.
- 30
31 (14) Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones,
32 Y.; Stuart, D.; Stammers, D. High Resolution Structures of HIV-1 RT from Four RT-Inhibitor
33 Complexes. *Nat. Struct. Mol. Biol.* **1995**, *2*, 293–302.
- 34
35 (15) Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A.; Hughes, S. H.;
36 Arnold, E. Structure of HIV-1 RT/TIBO R 86183 Complex Reveals Similarity in the Binding of
37 Diverse Nonnucleoside Inhibitors. *Nat. Struct. Mol. Biol.* **1995**, *2*, 407–415.
- 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (16) Engelman, A.; Cherepanov, P. The Structural Biology of HIV-1: Mechanistic and Therapeutic
4 Insights. *Nat. Rev. Microbiol.* **2012**, *10*, 279–290.
- 5
6
7 (17) Vassylyev, D. G.; Sekine, S.-i.; Laptenko, O.; Lee, J.; Vassylyeva, M. N.; Borukhov, S.;
8 Yokoyama, S. Crystal Structure of a Bacterial RNA Polymerase Holoenzyme at 2.6 Å Resolution.
9 *Nature* **2002**, *417*, 712–719.
- 10
11
12 (18) Kotler, M.; Becker, Y. Rifampicin and Distamycin A as Inhibitors of Rous Sarcoma Virus
13 Reverse Transcriptase. *Nat. New Biol.* **1971**, *234*, 212–214.
- 14
15
16 (19) Szilvay, A. M.; Stern, B.; Blichenberg, A.; Helland, D. E. Structural and Functional Similarities
17 between HIV-1 Reverse Transcriptase and the Escherichia coli RNA Polymerase β' Subunit. *FEBS*
18 *Lett.* **2000**, *484*, 43–47.
- 19
20
21 (20) Mukhopadhyay, J.; Das, K.; Ismail, S.; Koppstein, D.; Jang, M.; Hudson, B.; Sarafianos, S.;
22 Tuske, S.; Patel, J.; Jansen, R.; Irschik, H.; Arnold, E.; Ebright, R. H. The RNA Polymerase "Switch
23 Region" is a Target for Inhibitors. *Cell* **2008**, *135*, 295–307.
- 24
25
26 (21) Sahner, J. H.; Groh, M.; Negri, M.; Haupenthal, J.; Hartmann, R. W. Novel Small Molecule
27 Inhibitors Targeting the "Switch Region" of Bacterial RNAP: Structure-Based Optimization of a
28 Virtual Screening Hit. *Eur. J. Med. Chem.* **2013**, *65*, 223–231.
- 29
30
31 (22) Elgaher, W. A. M.; Fruth, M.; Groh, M.; Haupenthal, J.; Hartmann, R. W. Expanding the
32 Scaffold for Bacterial RNA Polymerase Inhibitors: Design, Synthesis and Structure–Activity
33 Relationships of Ureido-Heterocyclic-Carboxylic Acids. *RSC Adv.* **2014**, *4*, 2177–2194.
- 34
35
36 (23) Fruth, M.; Plaza, A.; Hinsberger, S.; Sahner, J. H.; Haupenthal, J.; Bischoff, M.; Jansen, R.;
37 Müller, R.; Hartmann, R. W. Binding Mode Characterization of Novel RNA Polymerase Inhibitors
38 Using a Combined Biochemical and NMR Approach. *ACS Chem. Biol.* **2014**, *9*, 2656–2663.
- 39
40
41 (24) Sharma, K. K.; Przybilla, F.; Restle, T.; Godet, J.; Mély, Y. FRET-Based Assay to Screen
42 Inhibitors of HIV-1 Reverse Transcriptase and Nucleocapsid Protein. *Nucleic Acids Res.* [Online early
43 access]. DOI: 10.1093/nar/gkv1532. Published Online: January 13, 2016.
- 44
45
46 (25) Srivastava, A.; Talaue, M.; Liu, S.; Degen, D.; Ebright, R. Y.; Sineva, E.; Chakraborty, A.;
47 Druzhinin, S. Y.; Chatterjee, S.; Mukhopadhyay, J.; Ebright, Y. W.; Zozula, A.; Shen, J.; Sengupta, S.;
48 Niedfeldt, R. R.; Xin, C.; Kaneko, T.; Irschik, H.; Jansen, R.; Donadio, S.; Connell, N.; Ebright, R. H.
- 49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 New Target for Inhibition of Bacterial RNA Polymerase: 'Switch Region'. *Curr. Opin. Microbiol.*
4
5 **2011**, *14*, 532–543.

6
7 (26) Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.;
8
9 Debouck, C.; Harrison, S. C. The Structure of Unliganded Reverse Transcriptase from the Human
10
11 Immunodeficiency Virus Type 1. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92*, 1222–1226.

12
13 (27) Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of Inhibition of
14
15 HIV-1 Reverse Transcriptase by Non-Nucleoside Inhibitors. *Nat. Struct. Mol. Biol.* **1995**, *2*, 303–308.

16
17 (28) Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. New 4-
18
19 Point Pharmacophore Method for Molecular Similarity and Diversity Applications: Overview of the
20
21 Method and Applications, Including a Novel Approach to the Design of Combinatorial Libraries
22
23 Containing Privileged Substructures. *J. Med. Chem.* **1999**, *42*, 3251–3264.

24
25 (29) Leeson, P. D.; Springthorpe, B. The Influence of Drug-Like Concepts on Decision-Making in
26
27 Medicinal Chemistry. *Nat. Rev. Drug Discov.* **2007**, *6*, 881–890.


28
29 (30) Domaoal, R. A.; Demeter, L. M. Structural and Biochemical Effects of Human
30
31 Immunodeficiency Virus Mutants Resistant to Non-Nucleoside Reverse Transcriptase Inhibitors. *Int.*
32
33 *J. Biochem. Cell Biol.* **2004**, *36*, 1735–1751.

34
35 (31) Pelemans, H.; Esnouf, R.; Clercq, E. de; Balzarini, J. Mutational Analysis of Trp-229 of Human
36
37 Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Identifies This Amino Acid Residue as a
38
39 Prime Target for the Rational Design of New Non-Nucleoside RT Inhibitors. *Mol. Pharmacol.* **2000**,
40
41 *57*, 954–960.

42
43 (32) Wohrl, B. M.; Krebs, R.; Thrall, S. H.; Le Grice, S. F. J.; Scheidig, A. J.; Goody, R. S. Kinetic
44
45 Analysis of Four HIV-1 Reverse Transcriptase Enzymes Mutated in the Primer Grip Region of p66.
46
47 Implications for DNA Synthesis and Dimerization. *J. Biol. Chem.* **1997**, *272*, 17581–17587.

48
49 (33) Smerdon, S. J.; Jäger, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P.
50
51 A.; Steitz, T. A. Structure of the Binding Site for Nonnucleoside Inhibitors of the Reverse
52
53 Transcriptase of Human Immunodeficiency Virus Type 1. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*,
54
55 3911–3915.
56
57
58
59
60

- 1
2
3 (34) Sharma, K. K.; Przybilla, F.; Restle, T.; Boudier, C.; Godet, J.; Mély, Y. Reverse Transcriptase
4 in Action: FRET-Based Assay for Monitoring Flipping and Polymerase Activity in Real Time. *Anal.*
5 *Chem.* **2015**, *87*, 7690–7697.
6
7
8 (35) Grohmann, D.; Godet, J.; Mély, Y.; Darlix, J.-L.; Restle, T. HIV-1 Nucleocapsid Traps Reverse
9 Transcriptase on Nucleic Acid Substrates. *Biochemistry* **2008**, *47*, 12230–12240.
10
11 (36) Spence, R.; Kati, W.; Anderson, K.; Johnson, K. Mechanism of Inhibition of HIV-1 Reverse
12 Transcriptase by Nonnucleoside Inhibitors. *Science* **1995**, *267*, 988–993.
13
14 (37) Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal Structure at 3.5 Å
15 Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor. *Science* **1992**, *256*, 1783–
16 1790.
17
18 (38) Dull, T.; Zufferey, R.; Kelly, M.; Mandel, R. J.; Nguyen, M.; Trono, D.; Naldini, L. A Third-
19 Generation Lentivirus Vector with a Conditional Packaging System. *J. Virol.* **1998**, *72*, 8463–8471.
20
21 (39) Balamane, M.; Varghese, V.; Melikian, G. L.; Fessel, W. J.; Katzenstein, D. A.; Shafer, R. W.
22 Panel of Prototypical Recombinant Infectious Molecular Clones Resistant to Nevirapine, Efavirenz,
23 Etravirine, and Rilpivirine. *Antimicrob. Agents Chemother.* **2012**, *56*, 4522–4524.
24
25 (40) Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D.; Boyer, P. L.; Lewi, P.; Janssen, P. A.; Kleim, J. P.;
26 Rösner, M.; Hughes, S. H.; Arnold, E. The Lys103Asn Mutation of HIV-1 RT: a Novel Mechanism of
27 Drug Resistance. *J. Mol. Biol.* **2001**, *309*, 437–445.
28
29 (41) Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to
30 Proliferation and Cytotoxicity Assays. *J. Immunol. Methods* **1983**, *65*, 55–63.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



119x56mm (150 x 150 DPI)